Active substance
Bendroflumethiazide
- US FDA 3
- NHS prices 2
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| NATURETIN-2.5 | 2.5MG | tablet · oral | APOTHECON | Discontinued | 7 Dec 1959 |
| NATURETIN-5 | 5MG | tablet · oral | APOTHECON | Discontinued | 7 Dec 1959 |
| NATURETIN-10 | 10MG | tablet · oral | APOTHECON | Discontinued | 7 Dec 1959 |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Bendroflumethiazide 2.5mg tablets | £0.73 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Bendroflumethiazide 5mg tablets | £1.01 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 26 May 2021 CORZIDE — safety-related labeling change
Labeling sections changed: Warnings and Precautions
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.